

Anti-GPC3/Glypican-3 Antibody (Codrituzumab)

Introduction

Codrituzumab (GC33) is a humanized monoclonal antibody that targets human GPC3 (Glypican-3) with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the surface of hepatocellular carcinoma (HCC) cells. Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth.

Product parameters

Alternative Names	RG7686, GC33, Chugai anti-Glypican
Target Accession	P51654
Target	GPC3 / Glypican-3
CAS number	1365267-33-9
Molecular Weight	145.5 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Human GPC3 CHOS cells were stained with Anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=2.142 nM.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

